original ) (raw )Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status
Enrico Mini
Journal of Clinical Oncology, 2017
View PDFchevron_right
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials
Ken Shimada
Clinical colorectal cancer, 2016
View PDFchevron_right
Our data on detailing metastasis localization and subtype characteristics in metastatic colorectal cancer patients treated with Bevacizumab
Pınar Özdemir Akdur
View PDFchevron_right
Primary tumor location as a prognostic factor in metastatic colorectal cancer
Heinz-josef Lenz
Journal of the National Cancer Institute, 2015
View PDFchevron_right
The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review
Katleen Janssens
Critical reviews in oncology/hematology, 2018
View PDFchevron_right
Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis
Mireia Gil Raga
Molecular and clinical oncology, 2017
View PDFchevron_right
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
Axel Grothey
British Journal of Cancer
View PDFchevron_right
Correlation of Tumor Location to Clinical Outcomes in Colorectal Cancer: A Single-institution Retrospective Analysis
Raffaele Macarone Palmieri
Anticancer Research, 2019
View PDFchevron_right
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
Viola Barucca , Diana Giannarelli , Luigi Rossi
OncoTargets and therapy, 2013
View PDFchevron_right
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
Michele Tursi
Journal of Cancer
View PDFchevron_right
KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Alberto Orta
Cells, 2020
View PDFchevron_right
Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)
noara alhusseini
2022
View PDFchevron_right
Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06
Ken Shimada
Journal of Clinical Oncology, 2016
View PDFchevron_right
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
Fred Bosman , Eva Budinska
BMC Cancer, 2013
View PDFchevron_right
Relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients
Giuseppe Aprile
Molecular oncology
View PDFchevron_right
Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC)
Phillip Parente
Journal of Clinical Oncology, 2017
View PDFchevron_right
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials
Fernando Rivera
British journal of cancer, 2018
View PDFchevron_right
Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer
Pilar Alfonso
Molecular cancer therapeutics, 2017
View PDFchevron_right
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Giuseppe Tonini
Oncotarget, 2015
View PDFchevron_right
Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
Masahiro Hirakawa
Scientific Reports, 2020
View PDFchevron_right
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
Atsuo Takashima
Frontiers in Oncology, 2021
View PDFchevron_right
Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
Tadas Zvirblis
Acta medica Lituanica, 2016
View PDFchevron_right
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
Devavrat Arya
Frontiers in Oncology, 2020
View PDFchevron_right
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
Halfdan Sorbye
PloS one, 2015
View PDFchevron_right
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
Maria Colombino
Journal of Translational Medicine, 2016
View PDFchevron_right